Gabexate mesylate (CAS: 56974-61-9) is a synthetic protease inhibitor that is used to prevent and treat various medical conditions, such as pancreatitis, disseminated intravascular coagulation (DIC), and postoperative complications. It works by inhibiting the activity of various enzymes involved in blood clotting and inflammation.
Chemical name: N-(trans-4-amino-cyclohexanecarbonyl)-L-arginine methyl ester methanesulfonate
Molecular formula: C20H34N6O5S
Formula weight: 466.59 g/mol
CAS No: 56974-61-9
Top ten keywords from Google:
Synonyms:
Health benefits of this product: Gabexate mesylate has demonstrated potential health benefits in several areas, particularly in the prevention and treatment of medical conditions associated with inflammation, blood clotting, and tissue damage. It may also have potential benefits for cancer prevention, although more research is needed in this area.
Potential effects: Gabexate mesylate has demonstrated efficacy in several preclinical and clinical studies in preventing and treating pancreatitis, DIC, and postoperative complications. It may also have potential benefits for reducing inflammation and tissue damage in other medical conditions, such as sepsis and acute lung injury. Additionally, gabexate mesylate may have potential benefits for cancer prevention by inhibiting tumor growth and metastasis.
Product mechanism: Gabexate mesylate works by inhibiting the activity of various enzymes involved in blood clotting, inflammation, and tissue damage, such as trypsin, thrombin, and plasmin. It is a serine protease inhibitor that binds to these enzymes and prevents their activation and subsequent downstream effects. By inhibiting these enzymes, gabexate mesylate can reduce the risk of blood clots, inflammation, and tissue damage in various medical conditions.
Safety: Gabexate mesylate has been evaluated in several clinical trials involving thousands of participants and has been generally well-tolerated. Rare but potential side effects may include headache, nausea, diarrhea, and allergic reactions. Patients with bleeding disorders or kidney disease should exercise caution when taking gabexate mesylate, as it may affect these conditions. Pregnant or breastfeeding women should avoid using gabexate mesylate, as its safety in these populations has not been established.
Side effects: Common side effects of gabexate mesylate may include headache, nausea, vomiting, diarrhea, and abdominal pain. These symptoms are usually mild or moderate and can be managed with supportive care or dose modifications. Less common but more severe side effects may include bleeding disorders, allergic reactions, and liver or kidney dysfunction, which may require prompt medical intervention. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.
Dosing information: The optimal dose and dosing regimen of gabexate mesylate may vary depending on the patient's condition and treatment goals. In clinical trials, doses ranging from 200 to 400 mg per day have been evaluated for pancreatitis and DIC. For postoperative complications, doses ranging from 200 to 600 mg per day have been evaluated. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.
Conclusion: Gabexate mesylate (CAS: 56974-61-9) is a synthetic protease inhibitor that is used to prevent and treat various medical conditions associated with inflammation, blood clotting, and tissue damage. It works by inhibiting the activity of various enzymes involved in these processes, leading to a range of potential health benefits. Although it has been generally well-tolerated, it may cause some side effects that should be monitored closely. More research is needed to determine its full potential and efficacy in different patient populations and its long-term safety profile
